论文部分内容阅读
目的：评价卵巢肿瘤组织中突变型ｐ５３基因和Ｐ－糖蛋白（Ｐ－ｇｐ）表达的临床病理意义及其相互关系。方法：采用免疫组织化学法测定卵巢恶性肿瘤５３例，卵巢良性肿瘤２０例和正常卵巢组织１７例的ｐ５３和Ｐ－ｇｐ的表达，并与临床病理因素进行相关分析。结果：１．卵巢恶性肿瘤组织中ｐ５３和Ｐ－ｇｐ阳性表达率分别为４６．７％和３５．８％，卵巢良性肿瘤和正常卵巢组织中则无一例ｐ５３和Ｐ－ｇｐ表达。２．Ⅲ～Ⅳ期患者和低分化卵巢恶性瘤组织中ｐ５３表达阳性率高于Ⅰ～Ⅱ期和高、中分化者，而Ｐ－ｇｐ表达与临床分期、组织学类型和分级无明显相关性。３．Ｐ－ｇｐ表达阳性和阴性的卵巢恶性肿瘤患者，对化疗的有效率分别为３１．６％和６４．７％，而ｐ５３阳性表达与化疗效果无明显相关性。结论：组织中的ｐ５３和Ｐ－ｇｐ表达测定对判断卵巢恶性肿瘤的预后和对化疗的敏感性有一定的价值。
Objective: To evaluate the clinicopathological significance and the relationship between the expression of mutant p53 gene and P-glycoprotein (P-gp) in ovarian tumor. Methods: The expressions of p53 and P-gp in 53 cases of ovarian malignant tumor, 20 cases of benign ovarian tumor and 17 cases of normal ovarian tissue were detected by immunohistochemistry, and the correlations were analyzed with clinicopathological factors. Results: 1. The positive rates of p53 and P-gp in ovary malignant tumor tissues were 46.7% and 35.8%, respectively. There was no p53 and P-gp expression in benign ovarian tumors and normal ovarian tissues. 2. The positive rate of p53 in stage Ⅲ ~ Ⅳ patients and poorly differentiated ovarian malignant tumors was higher than that in stage Ⅰ ~ Ⅱ and in moderate and high differentiated patients, while the expression of P-gp had no significant correlation with clinical stage, histological type and grade. 3. The positive rates of chemotherapy and chemotherapy for P-gp positive and negative ovarian cancer patients were 31.6% and 64.7%, respectively. There was no significant correlation between the positive expression of p53 and the efficacy of chemotherapy. Conclusion: The determination of p53 and P-gp expression in tissues is of value in judging the prognosis of ovarian cancer and the sensitivity to chemotherapy.